Soumerai SB, Ross-Degnan D. Inadequate prescription-drug coverage for medicare enrollees: a call
to action. N Engl J Med.1999;340:722-728.
Minister of Public Works and Government Services. Canadian Health Action: Building on the Legacy: Synthesis
Reports and Issues Papers. Ottawa, Ontario: National Forum on Health; 1997. Cat No. H21-126/5-2-1997E.
Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies:
research in need of discipline. Milbank Q.1993;71:217-252.
Levy R. Prescription cost sharing economic and health impacts, and implications
for health policy. Pharmacoeconomics.1992;2:219-237.
Huttin C. The use of prescription charges. Health Policy.1994;27:53-73.
Reeder CE, Lingle EW, Schulz RM.
et al. Economic impact of cost-containment strategies in third party programmes
in the US (part 1). Pharmacoeconomics.1993;4:92-103.
Hurley J, Arbuthnot Johnson N. The effects of co-payments within drug reimbursement programs. Can Public Policy.1991;17:473-489.
Ryan M, Birch S. Charging for health care: evidence on the utilisation of NHS prescribed
drugs. Soc Sci Med.1991;33:681-687.
Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on
Medicaid recipients. Med Care.1996;34:686-701.
Johnson RE, Goodman RM, Hornbrook MC, Eldredge MB. The effect of increased prescription drug cost-sharing on medical care
utilization and expenses of elderly health maintenance organization members. Med Care.1997;35:1119-1131.
Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost-sharing. Soc Sci Med.1985;21:1063-1069.
Harris BL, Stergachis A, Ried LD. The effect of drug co-payments on utilization and cost of pharmaceuticals
in a health maintenance organization. Med Care.1990;28:907-917.
O'Brien B. The effect of patient charges on the utilization of prescription medicines. J Health Econ.1989;8:109-132.
Smith DG. The effects of copayments and generic substitution on the use and costs
of prescription drugs. Inquiry.1993;30:189-198.
Nelson AA, Reeder CE, Dickson M. The effect of a Medicaid drug copayment program on the utilization
and cost of prescription services. Med Care.1984;22:724-736.
Lohr KN, Brook RH, Kamberg C.
et al. Use of medical care in the RAND health insurance experiment: diagnosis
and service-specific analyses in a randomized controlled trial. Santa Monica, Calif: RAND; 1986.
Reeder CE, Nelson AA. The differential impact of copayment on drug use in a Medicaid population. Inquiry.1985;22:396-403.
Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects
on therapy, cost, and equity. N Engl J Med.1987;317:550-556.
Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use
of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med.1994;331:650-655.
Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskkiy I. Effects of Medicaid drug-payment limits on admission to hospitals and
nursing homes. N Engl J Med.1991;325:1072-1077.
Brook RH, Ware JE, Rogers WH.
et al. Does free care improve adults' health? results from a randomized controlled
trial. N Engl J Med.1983;309:1426-1434.
Newhouse JP.The Insurance Experiment Group. Free for All? Lessons From the RAND Health Insurance Experiment . London, England: Harvard University Press; 1993.
Martin M. Quebec considering universal drug insurance. CMAJ.1996;154:1264.
World Health Organization. Essential drugs. WHO Drug Information.1999;13:249-262.
McGavock H, Wilson-Davis K, Niblock RWF. Unsuspected patterns of drug utilization revealed by interrogation
of a regional general practitioner prescribing database. Pharmacoepidemiol Drug Saf.1992;1:73-80.
Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of
the experimental literature. Milbank Q.1989;67:268-317.
Goetghebeur E, Molenberghs G, Katz J. Estimating the causal effect of compliance on binary outcomes in randomized
controlled trials. Stat Med.1998;17:341-355.
Morgenstern H. Ecological studies. In: Rothman K, Greenland S, eds. Modern Epidemiology. Philadelphia, Pa: Lippincott-Raven; 1998:459-480.
Tamblyn RM, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological
research: the accuracy and comprehensiveness of the prescription claims database
in Quebec. J Clin Epidemiol.1995;48:999-1009.
Tamblyn RM, Reid T, Mayo N, McLeod PJ, Churchill-Smith M. Using medical services claims to assess injuries in the elderly: the
sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol.2000;53:183-194.
Demers M. Cout des services médicaux durant la dernière
année de vie au Québec en 1991. Québec, Direction générale de l'évaluation
et du contrôle, Régie de l'assurance-maladie du Québec;
Tamblyn R, Abrahamowicz M. Drug utilization patterns. In: Armitage P, Coulton T, eds. Encyclopedia of
Biostatistics. West Sussex, England: John Wiley & Sons Ltd; 1998:1235-1247.
Wilkins K. Use of postal codes and addresses in the analysis of health data. Health Rep.1993;5:157-177.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal
studies: development and validation. J Chronic Dis.1987;40:373-383.
Deyo RA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative
data: a response. J Clin Epidemiol.1993;46:1075-1079.
Ward MM, Leigh JP. Pooled time series regression analysis in longitudinal studies. J Clin Epidemiol.1993;46:645-659.
Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrics.1986;73:13-22.
Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics.1986;42:121-130.
Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic
Rockhill B, Weinberg CR, Newman B. Population attributable fraction estimation for established breast
cancer risk factors: considering the issues of high prevalence and unmodifiability. Am J Epidemiol.1998;147:826-833.
Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication
adherence in the elderly. Ann Pharmacother.1998;32:749-754.
Inui TS, Carter WB, Pecoraro RE, Pearlman RA, Dohan JJ. Variations in patient compliance with common long-term drugs. Med Care.1980;18:986-993.
Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol.1997;50:619-625.
Lurie N, Ward NB, Shapiro MF, Gallego C, Vaghaiwalla R, Brook RH. Termination of medical benefits: a follow-up study one year later. N Engl J Med.1986;314:1266-1268.
Simon GE, Grothaus L, Durham ML, VonKorff M, Pabiniak C. Inpact of visit copayments on outpatient mental health utilization
by members of a health maintenance organization. Am J Psychiatry.1996;153:331-338.
Bloom BS, Jacobs J. Cost effects of restricting cost-effective therapy. Med Care.1985;23:872-879.
Simon GE, VonKorff M, Durham ML. Predictors of outpatient mental health utilization by primary care
patients in a health maintenance organization. Am J Psychiatry.1994;151:908-913.
Bacovsky RA. Federal, Provincial and Territorial Government-Sponsored Drug Plans
and Drug Databases. Health Canada 1997; Background information Prepared for the Conference
on National Approaches to Pharmacare on January 18-20, 1998 (Saskatoon, Saskatchewan).